Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer.

2.50
Hdl Handle:
http://hdl.handle.net/10541/99252
Title:
Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer.
Authors:
Howell, Anthony ( 0000-0002-6233-719X ) ; DeFriend, D; Robertson, J; Blamey, R; Walton, P
Abstract:
We treated 19 patients with advanced breast cancer resistant to tamoxifen with a new specific antioestrogen (ICI 182780) which, in animal studies, has no agonist activity. 13 (69%) patients responded (7 had partial responses and 6 showed no change) to monthly intramuscular injections of ICI 182780 after progression on tamoxifen, for a median duration of 18 months with minimum side effects. Preliminary evidence suggests that the agent is without effects on the liver or the hypothalamic-pituitary axis. ICI 182780 appears to be a promising new agent for treatment of advanced and early breast cancer.
Affiliation:
CRC Department of Medical Oncology, University of Manchester, Christie Hospital, UK.
Citation:
Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer. 1995, 345 (8941):29-30 Lancet
Journal:
Lancet
Issue Date:
7-Jan-1995
URI:
http://hdl.handle.net/10541/99252
DOI:
10.1016/S0140-6736(95)91156-1
PubMed ID:
7799704
Type:
Article
Language:
en
ISSN:
0140-6736
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorHowell, Anthonyen
dc.contributor.authorDeFriend, Den
dc.contributor.authorRobertson, Jen
dc.contributor.authorBlamey, Ren
dc.contributor.authorWalton, Pen
dc.date.accessioned2010-05-19T11:17:46Z-
dc.date.available2010-05-19T11:17:46Z-
dc.date.issued1995-01-07-
dc.identifier.citationResponse to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer. 1995, 345 (8941):29-30 Lanceten
dc.identifier.issn0140-6736-
dc.identifier.pmid7799704-
dc.identifier.doi10.1016/S0140-6736(95)91156-1-
dc.identifier.urihttp://hdl.handle.net/10541/99252-
dc.description.abstractWe treated 19 patients with advanced breast cancer resistant to tamoxifen with a new specific antioestrogen (ICI 182780) which, in animal studies, has no agonist activity. 13 (69%) patients responded (7 had partial responses and 6 showed no change) to monthly intramuscular injections of ICI 182780 after progression on tamoxifen, for a median duration of 18 months with minimum side effects. Preliminary evidence suggests that the agent is without effects on the liver or the hypothalamic-pituitary axis. ICI 182780 appears to be a promising new agent for treatment of advanced and early breast cancer.en
dc.language.isoenen
dc.subjectBreast Canceren
dc.subjectOestrogen Antagonistsen
dc.subject.meshAged-
dc.subject.meshAged, 80 and over-
dc.subject.meshAntineoplastic Agents-
dc.subject.meshBreast Neoplasms-
dc.subject.meshDrug Tolerance-
dc.subject.meshEstradiol-
dc.subject.meshEstrogen Antagonists-
dc.subject.meshFemale-
dc.subject.meshHumans-
dc.subject.meshInjections, Intramuscular-
dc.subject.meshTamoxifen-
dc.titleResponse to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer.en
dc.typeArticleen
dc.contributor.departmentCRC Department of Medical Oncology, University of Manchester, Christie Hospital, UK.en
dc.identifier.journalLanceten

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.